Indications for DEPO-PROVERA CI:

Injectable contraception.


Give by deep IM inj in the gluteal or deltoid muscle; rotate inj sites. 150mg every 3 months (13 weeks). Give 1st dose within 5 days of onset of normal menses (see full labeling for postpartum). Do not use for >2 years unless other methods are inadequate.


Pre-menarche: not applicable.


Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease. Breast carcinoma. Significant liver disease. Undiagnosed vaginal bleeding. Pregnancy.

Boxed Warning:

Loss of bone mineral density.


May lose significant bone mineral density (BMD). Evaluate BMD with long-term use or in adolescents. Risk for osteoporosis (eg, metabolic bone disease, anorexia, family history). Previous or family history of breast cancer (monitor closely). Ectopic pregnancy. History of depression; monitor for mood changes. Diabetes. Conditions aggravated by fluid retention; monitor. Do pretreatment physical exam. Discontinue if jaundice or elevated transaminases, visual disturbances, migraine, or thrombotic disorders occur. Nursing mothers.

See Also:

Pharmacologic Class:



May be antagonized by moderate or strong CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil, rifampin, carbamazepine, phenytoin, phenobarbital, mitotane, St. John's wort, others); avoid. May reduce bone mass with anticonvulsants, corticosteroids; avoid alcohol, tobacco. May be affected by protease inhibitors, NNRTIs. May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.

Adverse Reactions:

Dysfunctional uterine bleeding, headache, increased weight, amenorrhea, inj site reactions, vaginitis, abdominal pain, UTIs, acne; decreased BMD, anaphylaxis.

How Supplied:

Vials—1, 25; Prefilled syringe (1mL)—1 (w. needles); SubQ (prefilled syringe)—1 (w. needle)